Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature

Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature

Abstract Background Gallbladder cancer (GBC) is the most common and aggressive extra hepatic biliary tree cancer (BTC) with dismal outcome. Complete surgical resection is the treatment of choice. Chemotherapy is used for palliation in advanced GBC where surgery is not possible, and the most commonly...

Full description

Bibliographic Details
Main Authors: Kishan Soni, Tarun Kumar, Manoj Pandey
Format: Article
Language:English
Published: BMC 2020-07-01
Series:World Journal of Surgical Oncology
Subjects:
Gallbladder cancer
Tyrosine kinase inhibitors
Gemcitabine
Erlotinib
Chemotherapy
Online Access:http://link.springer.com/article/10.1186/s12957-020-01934-4

Similar Items

Similar Items